ELDN | Eledon Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.59 - 5.44
52 Week Range	1.0700 - 5.54
Beta	0.77
Implied Volatility	75.35%
IV Rank	26.14%
Day's Volume	597,185
Average Volume	300,590
Shares Outstanding	58,011,877
Market Cap	280,197,366
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-09-17

Valuation
Profitability
Growth
Health
P/E Ratio	10.73
Forward P/E Ratio	N/A
EPS	0.45
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	20
Country	USA
Website	ELDN

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

ELDN's peers: BIVI, PTIX, CMMB, CRMD, DAWN, DTIL, ABVC, INZY, TERN, HOOK, XFOR, ABOS, AMLX, MREO, ETON, HRTX, IFRX, JSPR, MDXH, MESO, MGTX, RNXT, RZLT, SPRB, TARS, VCNX, VRCA, XBIT, GPCR

*Chart delayed

Analyzing fundamentals for ELDN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see ELDN Fundamentals page.

Watching at ELDN technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ELDN Technicals page.